13.12.2017 • News

PMC Buys Isochem’s Pharma Business

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

PMC Group France, a wholly owned subsidiary of US-based PMC Group International, has acquired the pharmaceuticals business of France’s Isochem for an undisclosed sum.

The business comprises research, product and process development capabilities as well as pilot-scale and full plant-scale production of drug intermediates and APIs for major companies worldwide.

Isochem operates three sites at Gennevilliers, Pithiviers and Vert-le-Petit, all within a 60-mile radius of Paris and audited by the US Food and Drug Administration (FDA) as cGMP-compliant.

Going forward, the company will be known as PMC Isochem, operating as a wholly owned subsidiary of PMC Group France.

The acquisition follows the October purchase of Indian pharma Yegna Manojavam Drugs and Chemicals by PMC Group subsidiary, PMC YM-Pharma. The Indian company’s cGMP plant is claimed to be one of the largest fluoroquinolone drug manufacturing facilities in France.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read